One of the strongest prognosticators for MCL is mutations of TP53. 11,16 Lin et al17 suggested a role of AlloSCT for these patients; however, in our study, only 3 patients with TP53 mutations (all early POD) underwent AlloSCT, and all progressed again within 1 year of transplant. Here, TP53 is linked to mantle cell lymphoma.